FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376871003> ?p ?o ?g. }

• W4376871003 endingPage "683" @default.
• W4376871003 startingPage "673" @default.
• W4376871003 abstract "ABSTRACTABSTRACTIntroduction The advent of immunotherapy has revolutionized the treatment of cancer; anti-tumor efficacy has been observed with immune checkpoint inhibitors (ICI) in ~20 different cancer types with durable responses in some cases. However, the risk of toxicity in the form of immune-related adverse events (irAE) partially counterbalances these benefits, and there are no FDA-approved biomarkers to categorize patients by likelihood of response or risk of irAEs.Areas covered We conducted a thorough review of the literature of clinical studies regarding ICI and their toxicities. In this review, we synthesize the current body of literature about ICI treatment and irAE by summarizing the classes and uses of ICI, how to identify patients at risk for irAE, present the current understanding of irAE development, describe ongoing research into biomarkers of irAE, examine opportunities for irAE prevention, described management of steroid refractory irAE, and highlight future directions for development of prevention and management strategies.Expert opinion While ongoing biomarker studies are promising, it is unlikely that there will be a ‘one-size-fits-all’ approach to categorizing irAE risk. In contrast, improved management and irAE prophylaxis are potentially in reach, and ongoing trials will help elucidate best practices.KEYWORDS: Biomarkersimmune checkpoint inhibitorsimmunotherapyimmune-related adverse eventstoxicity Article highlights Biomarkers of ICI response include PD-L1 expression, TMB, MSI status, development of irAE, fecal microbiome composition, and TIL subtypePatients with autoimmune disease are able to be treated with ICI, though there is risk of disease flare with treatmentHypothesized mechanisms of irAE include antigen overlap between the tumor and affected organ, direct action on the affected organ, and altered cytokine signalingWhile no approved biomarkers of toxicity exist, possibilities include pre-treatment WBC counts, cytokine levels, specific auto-antibodies, and microbiome evaluationOngoing work examining IL-6 blockade may support a role for prophylaxis against or treatment of irAEManagement of steroid refractory irAE may benefit from early initiation of non-steroidal immunomodulators including infliximab and abatacept, though prospective clinical trials are needed to balance toxicity management with treatment efficacyDeclaration of interestDB Johnson has served on advisory boards or as a consultant for BMS, Catalyst Biopharma, Iovance, Jansen, Mallinckrodt, Merck, Mosaic ImmunoEngineering, Novartis, Oncosec, Pfizer, Targovax, and Teiko, has received research funding from BMS and Incyte, and has patents pending for use of MHC-II as a biomarker for immune checkpoint inhibitor response, and abatacept as treatment for immune-related adverse events.The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.Reviewer disclosuresPeer reviewers on this manuscript have no relevant financial or other relationships to disclose.Additional informationFundingThis paper received funding from NIH/NCI T32 CA217834-05." @default.
• W4376871003 created "2023-05-18" @default.
• W4376871003 creator A5025067315 @default.
• W4376871003 creator A5031858011 @default.
• W4376871003 creator A5065010794 @default.
• W4376871003 date "2023-05-22" @default.
• W4376871003 modified "2023-09-23" @default.
• W4376871003 title "Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity" @default.
• W4376871003 cites W1585093095 @default.
• W4376871003 cites W2085247907 @default.
• W4376871003 cites W2087757222 @default.
• W4376871003 cites W2107556275 @default.
• W4376871003 cites W2109485845 @default.
• W4376871003 cites W2109653150 @default.
• W4376871003 cites W2112121482 @default.
• W4376871003 cites W2119198740 @default.
• W4376871003 cites W2131950300 @default.
• W4376871003 cites W2139591061 @default.
• W4376871003 cites W2152897456 @default.
• W4376871003 cites W2156353875 @default.
• W4376871003 cites W2160834915 @default.
• W4376871003 cites W2166662937 @default.
• W4376871003 cites W2259730793 @default.
• W4376871003 cites W2293531514 @default.
• W4376871003 cites W2301707196 @default.
• W4376871003 cites W2401455386 @default.
• W4376871003 cites W2414977199 @default.
• W4376871003 cites W2418354692 @default.
• W4376871003 cites W2506616866 @default.
• W4376871003 cites W2527905628 @default.
• W4376871003 cites W2529484692 @default.
• W4376871003 cites W2547133566 @default.
• W4376871003 cites W2549481046 @default.
• W4376871003 cites W2560367415 @default.
• W4376871003 cites W2572174216 @default.
• W4376871003 cites W2582671354 @default.
• W4376871003 cites W2593747853 @default.
• W4376871003 cites W2606367731 @default.
• W4376871003 cites W2736166064 @default.
• W4376871003 cites W2739132742 @default.
• W4376871003 cites W2743419024 @default.
• W4376871003 cites W2744982342 @default.
• W4376871003 cites W2752793362 @default.
• W4376871003 cites W2753432434 @default.
• W4376871003 cites W2766903152 @default.
• W4376871003 cites W2781484625 @default.
• W4376871003 cites W2782333299 @default.
• W4376871003 cites W2783137027 @default.
• W4376871003 cites W2786396800 @default.
• W4376871003 cites W2791673886 @default.
• W4376871003 cites W2792937256 @default.
• W4376871003 cites W2797068438 @default.
• W4376871003 cites W2797429263 @default.
• W4376871003 cites W2805592007 @default.
• W4376871003 cites W2805968856 @default.
• W4376871003 cites W2883806089 @default.
• W4376871003 cites W2889824011 @default.
• W4376871003 cites W2891486030 @default.
• W4376871003 cites W2893824814 @default.
• W4376871003 cites W2893960509 @default.
• W4376871003 cites W2897422388 @default.
• W4376871003 cites W2897516580 @default.
• W4376871003 cites W2900360032 @default.
• W4376871003 cites W2911812451 @default.
• W4376871003 cites W2912364350 @default.
• W4376871003 cites W2913558101 @default.
• W4376871003 cites W2913745075 @default.
• W4376871003 cites W2915708315 @default.
• W4376871003 cites W2919778409 @default.
• W4376871003 cites W2924289105 @default.
• W4376871003 cites W2925446385 @default.
• W4376871003 cites W2939940798 @default.
• W4376871003 cites W2942467666 @default.
• W4376871003 cites W2950056455 @default.
• W4376871003 cites W2956028371 @default.
• W4376871003 cites W2964133630 @default.
• W4376871003 cites W2976652879 @default.
• W4376871003 cites W2976744492 @default.
• W4376871003 cites W2977392388 @default.
• W4376871003 cites W2982786601 @default.
• W4376871003 cites W2988124258 @default.
• W4376871003 cites W2997351648 @default.
• W4376871003 cites W3005376436 @default.
• W4376871003 cites W3009244677 @default.
• W4376871003 cites W3010839046 @default.
• W4376871003 cites W3011192052 @default.
• W4376871003 cites W3011243232 @default.
• W4376871003 cites W3012770963 @default.
• W4376871003 cites W3015079516 @default.
• W4376871003 cites W3016525073 @default.
• W4376871003 cites W3021794875 @default.
• W4376871003 cites W3047192227 @default.
• W4376871003 cites W3082951021 @default.
• W4376871003 cites W3085427829 @default.
• W4376871003 cites W3085860981 @default.
• W4376871003 cites W3087464965 @default.
• W4376871003 cites W3097511760 @default.
• W4376871003 cites W3107738233 @default.

• next